bonyf N.V (MLBON) Fair Value & Analysis
Healthcare · FR · Market cap €2.5M
Fair value as of: Jun 25, 2026
Analysis
bonyf N.V (MLBON) currently trades at €4.20, while our model-based Fair Value estimate is €3.01 — implying the stock looks roughly 28.3% overvalued today. We read business quality at 86/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
bonyf N.V. engages in the research, development, production, and distribution of oral and dental products in Belgium and internationally. The company offers PerioTabs, a brushing solution for gums, teeth, and dental implants to help reduce gingivitis, periodontitis, peri-mucositis, and peri-implantitis; and AphtoFix, a film-forming cream for the local treatment of mouth ulcers. It also provides denture care products, such as OlivaFix denture adhesive creams and NitrAdine disinfecting denture tabs; Denture Repair-fix, an instant repair system for broken or cracked dentures and teeth detached from dentures; Fixobridge, a ready to use cement that fixes dislodged crowns, inlays, and bridges; denture relining cushion for ill-fitting dentures; Effervescent denture cleanser tablets; Superior denture adhesive creams; and Cavifix, a synthetic resin-based filling material to temporarily seal newly formed cavities and repair lost fillings or inlays. In addition, the company offers orthodontic …
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is bonyf N.V (MLBON) undervalued?
What is the fair value of MLBON?
What is the quality score of MLBON?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.